2024-04-25-上交所-健康元药业集团股份有限公司2024年第一季度报告（英文版）_14页_288kb

Financial Performance Summary

Overview: Joincare Pharmaceutical Group Industry Co., Ltd. reported a 2024 first-quarter performance with mixed results. Revenue decreased by 4.81% to RMB 4.34 billion, while net profit attributable to shareholders slid 4.96% to RMB 439.8 million. Net profit after extraordinary gains and losses fell 4.26% to RMB 427.8 million. The company saw a significant improvement in operating cash flow, up 291.91% to RMB 972.3 million, primarily due to reduced procurement and expense. Key financial indicators such as basic earnings per share and weighted average return on net assets weakened slightly.

Revenue Breakdown: Sales from core product categories showed notable variations. Chemical pharmaceuticals revenue decreased 4.86%, with gonadotropic hormones increasing by 39.89%, gastroenterology products down 25.68%, respiratory products down 18.17%, and psychiatry products up 10.11%. API and intermediates products revenue declined 3.70%, traditional Chinese medicine products fell 28.38%, while diagnostic reagents increased 60.26%, and healthcare products surged 96.50% in revenue.

Extraordinary Items: The quarter included extraordinary gains and losses totaling RMB 12.04 million net. Key components included government grants of RMB 23.95 million, financial gains from fair value changes, and minority equity earnings, partially offset by non-operating expenses. Tax adjustments and minority entitlements influenced the overall impact.

Balance Sheet Changes: Assets totaled RMB 36.46 billion, up 0.29%, driven by increases in cash management but reduced by a drop in short-term loans. Liabilities decreased, with improved financial stability, while equity grew slightly, reflecting retained earnings and minority investor contributions. Changes included increased other receivables, new cash management activities, and fluctuations in investments and taxes.

Shareholder Information: As of March 31, 2024, total ordinary shareholders numbered 78,332. The top holder was Shenzhen Baiyeyuan Investment Co., Ltd. with 47.98% stake, followed by foreign investors and others. No significant acting-in-concert relationships were identified. Share holdings remained unchanged from the previous period.

Additional Notes: The company confirmed no extraordinary gains beyond standard disclosures and provided unaudited financial statements. Overall, while revenue and profit faced pressures, operational efficiencies boosted cash flow, and emerging product categories showed promise for future performance.